Catalyst Funds Management’s Taysha Gene Therapies TSHA Stock Holding History

Catalyst Funds Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,100	Closed	-$67.5K	–	886
2026 Q1	$67.5K	Buy	+15,100	New	+$70.2K	0.01%	520
2025 Q2	–	Sell	-11,900	Closed	-$16.5K	–	692
2025 Q1	$16.5K	Buy	+11,900	New	+$19.9K	﹤0.01%	442

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Catalyst Funds Management's TSHA Position: Q2 2026 in Review

Catalyst Funds Management sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 15,100 shares — an estimated $67.5K sold.

Catalyst Funds Management first reported a position in TSHA in Q1 2025 and held it in 2 quarters. The position peaked at $67.5K in Q1 2026. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Catalyst Funds Management reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
Catalyst Funds Management sold 15,100 Taysha Gene Therapies shares in Q2 2026, an estimated $67.5K.
Catalyst Funds Management first reported a position in Taysha Gene Therapies in Q1 2025 and held it in 2 quarters.
Catalyst Funds Management's Taysha Gene Therapies position peaked at $67.5K in Q1 2026.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.